These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24145699)

  • 1. Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).
    Marsh EB; Gottesman RF; Hillis AE; Urrutia VC; Llinas RH
    Medicine (Baltimore); 2013 Nov; 92(6):317-323. PubMed ID: 24145699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis.
    Zhu J; Shen X; Han C; Mei C; Zhou Y; Wang H; Kong Y; Jiang Y; Fang Q; Cai X
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104363. PubMed ID: 31501038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Four-Year Experience of Symptomatic Intracranial Hemorrhage Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center.
    Orlando A; Wagner JC; Fanale CV; Whaley M; McCarthy KL; Bar-Or D
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):969-76. PubMed ID: 26856464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA.
    Shah K; Clark A; Desai SM; Jadhav AP
    Neurocrit Care; 2022 Feb; 36(1):123-129. PubMed ID: 34228264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
    Amlie-Lefond C; Shaw DWW; Cooper A; Wainwright MS; Kirton A; Felling RJ; Abraham MG; Mackay MT; Dowling MM; Torres M; Rivkin MJ; Grabowski EF; Lee S; Kurz JE; McMillan HJ; Barry D; Lee-Eng J; Ichord RN
    Stroke; 2020 Feb; 51(2):542-548. PubMed ID: 31842706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
    Nisar T; Hanumanthu R; Khandelwal P
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104360. PubMed ID: 31501036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
    Whiteley WN; Thompson D; Murray G; Cohen G; Lindley RI; Wardlaw J; Sandercock P;
    Stroke; 2014 Apr; 45(4):1000-6. PubMed ID: 24603072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke.
    Liu M; Pan Y; Zhou L; Wang Y
    PLoS One; 2017; 12(9):e0184646. PubMed ID: 28922363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory factors associated with symptomatic hemorrhagic conversion of acute stroke after systemic thrombolysis.
    Kamal H; Mehta BK; Ahmed MK; Kavak KS; Zha A; Lail NS; Shirani P; Al-Mufti F; Sawyer RN; Mowla A
    J Neurol Sci; 2021 Jan; 420():117265. PubMed ID: 33333324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
    Chang A; Llinas EJ; Chen K; Llinas RH; Marsh EB
    Stroke; 2018 Jun; 49(6):1521-1524. PubMed ID: 29686025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis.
    James B; Chang AD; McTaggart RA; Hemendinger M; Mac Grory B; Cutting SM; Burton TM; Reznik ME; Thompson B; Wendell L; Mahta A; Siket M; Madsen TE; Sheth KN; Nouh A; Furie KL; Jayaraman MV; Khatri P; Yaghi S
    J Neurol Neurosurg Psychiatry; 2018 Aug; 89(8):866-869. PubMed ID: 29487169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
    Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED
    JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous Tissue Plasminogen Activator in Stroke Mimics.
    Ali-Ahmed F; Federspiel JJ; Liang L; Xu H; Sevilis T; Hernandez AF; Kosinski AS; Prvu Bettger J; Smith EE; Bhatt DL; Schwamm LH; Fonarow GC; Peterson ED; Xian Y
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005609. PubMed ID: 31412730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
    Xian Y; Federspiel JJ; Grau-Sepulveda M; Hernandez AF; Schwamm LH; Bhatt DL; Smith EE; Reeves MJ; Thomas L; Webb L; Bettger JP; Laskowitz DT; Fonarow GC; Peterson ED
    JAMA Neurol; 2016 Jan; 73(1):50-9. PubMed ID: 26551916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy.
    Vellimana AK; Yarbrough CK; Blackburn S; Strom RG; Pilgram TK; Lee JM; Grubb RL; Rich KM; Chicoine MR; Dacey RG; Derdeyn CP; Zipfel GJ
    Neurosurgery; 2014 Mar; 74(3):254-61. PubMed ID: 24335814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein level on admission is not associated with postintravenous thrombolysis intracranial hemorrhage in patients with acute ischemic stroke.
    Hong CT; Chiu WT; Chi NF; Lai LY; Hu CJ; Hu HH; Chan L
    J Investig Med; 2019 Mar; 67(3):659-662. PubMed ID: 30367009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of general anesthesia, baseline ASPECTS, time to treatment, and IV tPA on intracranial hemorrhage after neurothrombectomy: pooled analysis of the SWIFT PRIME, SWIFT, and STAR trials.
    Raychev R; Saver JL; Jahan R; Nogueira RG; Goyal M; Pereira VM; Gralla J; Levy EI; Yavagal DR; Cognard C; Liebeskind DS
    J Neurointerv Surg; 2020 Jan; 12(1):2-6. PubMed ID: 31239326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR.
    Mowla A; Memon A; Razavi SM; Lail NS; Vaughn CB; Mohammadi P; Sawyer RN; Shirani P
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105678. PubMed ID: 33640783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.